Quantcast
Home > Quotes > NAVB

Navidea Biopharmaceuticals, Inc. Common Stock (NAVB) Quote & Summary Data

NAVB 
$0.1351
*  
0.0061
4.73%
Get NAVB Alerts
*Delayed - data as of Mar. 19, 2019 11:04 ET  -  Find a broker to begin trading NAVB now
Exchange:AMEX
Industry: Health Care
Community Rating:
View:    NAVB Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
Today's High / Low
$ 0.145 / $ 0.129
Share Volume
275,056
90 Day Avg. Daily Volume
547,494
Previous Close
$ 0.129
52 Week High / Low
$ 0.4091 / $ 0.1005
Market Cap
24,573,434
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.26

Intraday Chart

Shares Traded

Share Volume:
275,056
90 Day Avg. Daily Volume:
547,494

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -0.10

Trading Range

The current last sale of $0.1351 is 34.43% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.145 $ 0.4091
 Low: $ 0.129 $ 0.1005

Company Description (as filed with the SEC)

Navidea Biopharmaceuticals, Inc. ("Navidea," the "Company," or "we"), a Delaware corporation (NYSE American: NAVB), is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on our Manocept(TM) platform to enhance patient care by identifying the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.  ... More ...  



Research Brokers before you trade

Want to trade FX?

Analyst Info